Jia Xu, Duan Xuanchu
Department of Ophthalmology, The Second Xiangya Hospital of Central South University, Changsha 410011, China.
Department of Ophthalmology, The Second Xiangya Hospital of Central South University, Changsha 410011, China; Email:
Zhonghua Yan Ke Za Zhi. 2015 Apr;51(4):314-8.
Neovascular glaucoma (NVG) is a group of secondary glaucoma which led by a variety of diseases that have anoxia or ischemia to the retina. Some studies have found that the etiology was related to the vascular endothelial growth factor (VEGF). At present, anti-VEGF as a treatment method to NVG, has become an important advance in the field of glaucoma research, which established a new way to improve the prognosis. This review mainly focused on the pathophysiologic basis and clinical research of NVG, fundamental research and applications about four kinds of anti-VEGF agents (Bevacizumab, Ranibizumab, Pegaptanib and Aflibercept) and application of treatment of NVG and anti-scarring in filtering surgery. The review also provided references for the clinical treatment of NVG and improving the success rate of operation.
新生血管性青光眼(NVG)是一组由多种导致视网膜缺氧或缺血的疾病所引发的继发性青光眼。一些研究发现其病因与血管内皮生长因子(VEGF)有关。目前,抗VEGF作为治疗NVG的一种方法,已成为青光眼研究领域的一项重要进展,为改善预后开辟了新途径。本综述主要聚焦于NVG的病理生理基础与临床研究、四种抗VEGF药物(贝伐单抗、雷珠单抗、哌加他尼和阿柏西普)的基础研究与应用以及NVG治疗和抗瘢痕在滤过性手术中的应用。该综述也为NVG的临床治疗及提高手术成功率提供了参考。